Every Form 4 that PROTAGENIC THERAPEUTICS (PTIX) has filed with the SEC in the last 12 months is listed below, newest first, and each one links through to the document itself with the summary and the scores our analysis gives it.
A Form 4 covers the transactions officers, directors and large holders report, so if you follow PTIX and want that one kind of document rather than the whole filing history, this is the page to keep. The company's other filings, of every form, are on the full PTIX filings page.
Protagenic Therapeutics, Inc. (PTIX) reported an insider open-market purchase by Executive Chair and Principal Officer Armen Garo H. On 2026-08-21, he purchased 20,000 shares of common stock at $0.65 per share. Following this transaction, he directly owns 73,533 common shares.
Protagenic Therapeutics, Inc. (PTIX) reported an insider share purchase by executive chair and principal officer, as well as director, Armen Garo H. On August 20, 2026, he purchased 16,634 shares of common stock in an open market or private transaction at $0.5898 per share, increasing his direct holdings to 53,533 shares. The filing indicates the Rule 10b5-1 trading plan checkbox was not selected.
Protagenic Therapeutics, Inc. (PTIX) reported that director and executive chair Armen Garo H purchased 2,700 shares of common stock on 2026-08-19 in an open-market or private transaction at $0.35 per share. Following this purchase, he directly owns 36,899 common shares. The transaction was not indicated as pursuant to a Rule 10b5-1 trading plan.
Protagenic Therapeutics, Inc. director and executive chair Armen Garo H reported an open-market purchase of common stock. On 2026-08-11, he purchased 2,220 shares at $0.32 per share, bringing his directly held position to 34,199 common shares. The transaction was reported as a direct ownership purchase and not under a Rule 10b5-1 trading plan.
Protagenic Therapeutics, Inc. director and executive chair Armen Garo reported purchasing 685 shares of common stock on 2026-08-06 at $0.22 per share in an open-market or private transaction. Following this transaction, his directly owned holdings total 31,979 common shares.
Protagenic Therapeutics, Inc. director and executive chair Armen Garo H purchased 5,000 shares of common stock on August 5, 2026 at $0.2588 per share in an open-market or private transaction. Following this buy, he directly holds 31,294 common shares. The transaction was not reported as made under a Rule 10b5-1 trading plan.
Protagenic Therapeutics, Inc. executive chair and principal officer Armen Garo purchased 26,291 shares of common stock on July 30, 2026 at $0.1828 per share in an open-market or private transaction. After this trade, he holds 26,291 Protagenic Therapeutics shares directly.